GENERIC NAME: raloxifene
BRAND NAME: Evista
GENERIC AVAILABLE: Yes
- Evista is prescribed for the prevention and treatment of osteoporosis in post-menopausal women.
- Supplemental vitamin D should be added to the diet if daily intake is not adequate.
WARNING: (BLACK BOX WARNING):
- Evista may increase the risk of deep vein thrombosis (DVT) and pulmonary embolism. Therefore, women with active or past history of venous thromboembolism should not take Evista.
- Evista increased the risk of death from stroke in a clinical trial of postmenopausal women with a history of coronary heart disease or women with a high risk of serious heart related conditions. Consider risk-benefit balance in women at risk for stroke.
The most common side effects of Evista are:
Other side effects include:
Possible serious side effects include:
Evista may increase blood triglyceride levels in some individuals Evista increases the risk of blood clots, including stroke, deep vein thrombosis (DVT), and pulmonary embolism (blood clots in the lung). The greatest increase in risk occurs during the first 4 months of use. Patients taking Evista should avoid prolonged periods of restricted movement during travel when blood clots are more prone to occur. Patients should move around periodically during long trips.
Quick GuideWhat Is Osteoporosis? Treatment, Symptoms, Medication
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.